Influence of operational variables in multi-particulate delayed release systems for colon-targeted drug delivery of celecoxib using extrusion spheronization

Main Article Content

V R Sinha
A Aggarwal
S Srivastava

Abstract

The present research was aimed to formulate and evaluate pH and time-dependent multiparticulate systems for colon-targeted drug delivery of celecoxib (CXB) with maximum drug absorption, reduced peak plasma fluctuations, and minimum potential side effects. Multiple unit delayed release systems of the drug in MCC (Avicel® PH-102) grade  were prepared using polymethacrylate polymers (Eudragit® L-100 and RSPO) as a granulating binder by the extrusion- spheronization technique and characterized for their shape, size, size distribution, friability, density, and moisture content. In vitro release studies were performed in 0.1N HCl, for first 2 h then further performed in phosphate buffer (pH 6.8) for 24 h. The resulting pellets were prepared by extrusion spheronization using different grades of polymethacrylate polymers
as a granulating binder, showing a substantial decrease in drug release in initial 5 h (16.28-16.7%) and releasing most of the drug in 12-24 h. The geometric and arithmetic mean diameter ranged from (490 to 780 μm) and (636 to 734 μm),
respectively. The minimum to maximum range for circularity, elongation and rectangle were found to be (0.847±0.009 to0.965±0.078), (1.036±0.057 to 1.185±0.023), and (0.724±0.041 to 0.791±0.047) respectively showing the proper shape and size of the pellets. The content of CXB in the prepared pellets was observed between 98.70 and 99.47% justifying the uniform drug distribution. The in vitro dissolution studies showed that the retardant effect in initial 5 h and most of the drug release in 24 h depended on the ratio and concentration of different grades of methacrylate polymers used in the formulation. CXB-loaded MUPS prepared by the extrusion-spheronization technique using polymethacrylate polymers showed immense potential for colon-specific drug delivery of the drug.

Downloads

Download data is not yet available.

Article Details

How to Cite
Sinha, V. R., Aggarwal, A., & Srivastava, S. (2014). Influence of operational variables in multi-particulate delayed release systems for colon-targeted drug delivery of celecoxib using extrusion spheronization. Asian Journal of Pharmaceutics (AJP), 4(2). https://doi.org/10.22377/ajp.v4i2.132
Section
Articles

References

Adkin DA, Davis SS, Sparrow RA, Wilding IR. Colonic transit of different

sized tablets in healthy subjects. J Control Rel 1993;23:147-53.

Jackson-Thompson J, Ahmed F, German RR, Lai SM, Friedman C.

Descriptive epidemiology of colorectal cancer in the United States,

-2001. Cancer 2006;107:1103-11.

Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Eudragit-

coated pectin microspheres of 5-fluorouracil for colon targeting. AAPS

PharmSciTech 2007;8:12.

Sinha V, Singh A, Kumar RV, Singh S, Kumria R, Bhinge J. Oral colon-

specific drug delivery of protein and peptide drugs. Crit Rev Ther Drug

Carrier Syst 2007;24:63-92.

Soh JW, Kazi JU, Li H, Thompson WJ, Weinstein IB. Celecoxib-induced

growth inhibition in SW480 colon cancer cells is associated with

activation of protein kinase G. Mol Carcinog 2008;47:519-25.

Dianzani C, Brucato L, Gallicchio M, Rosa AC, Collino M, Fantozzi R.

Celecoxib modulates adhesion of HT29 colon cancer cells to vascular

endothelial cells by inhibiting ICAM-1 and VCAM-1 expression. Br J

Pharmacol 2008;153:1153-61.

Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib

for the prevention of colorectal adenomatous polyps. N Engl J Med

;355:885-95.

Youan BB. Chronopharmaceutics: Gimmick or clinically relevant

approach to drug delivery? J Control Release 2004;98:337-53.

Basit AW. Advances in colonic drug delivery. Drugs 2005;65:1991-2007.

Goodhardt FW, Draper JR, Ninger FC. Design and use of laboratory

extruder for pharmaceutical granulations. J Pharm Sci 1973;62:132-6.

Koo OM, Heng PW. The influence of microcrystalline cellulose grade

on shape and shape distributions of pellets produced by extrusion-

spheronization. Chem Pharm Bull (Tokyo) 2001;49:1383-7.

Bolton S. Pharmaceutical statistics: Practical and Clinical applications.

Basel, New York: Marcel Dekker, Inc; 1997. p. 14-20.

Heng PW, Koo OM. A study of the effects of the physical characteristics of microcrystalline cellulose on performance in extrusion spheronization.

Pharm Res 2001;18:480-7.

US Pharmacopoeia 30/NF25. US Pharmacopoeial Convention, Rockville,

MD, 2007. Chapman SR, Rowe RC, Newton JM. Characterization of the sphericity of particles by the one plane critical stability. J Pharm Pharmacol

;40:503-5.

Gupta VK, Beckert TE, Price JC. A novel pH- and time- based multi-unit

potential colonic drug delivery system. I. Development. Int J Pharm

;213:83-91.

Krogars K, Heinamaki J, Vesalathi J, Marvola M, Antikainen O, Yliruusi

J. Extrusion-spheronisation of pH- sensitive polymeric matrix pellets

for possible colonic drug delivery. Int J Pharm 2000;199:187-94.